A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

In hormone-sensitive prostate cancer, an alternative dosing of docetaxel plus Nubeqa and ADT was associated with improvements in side effect rates.

Key Takeaways Combining enzalutamide with standard hormone therapy cut the risk of prostate cancer death by over 40% in a ...

Dave Riley, from East Lancashire Prostate Cancer Support, said men over 50 can get tested annually, but "you can get checked ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without ...

BERLIN -- Adding a test that predicts cancer signal origin to single standard of care (SoC) screening substantially increased ...

The Galleri test aims to find fragments of DNA in a person’s blood that can indicate the presence of a cancerous tumor.

Prostate cancer is the most common form of cancer in the UK, according to Prostate Cancer UK. Cancer Research UK says ...

Two cancer experts go head to head, arguing the case for and against a targeted prostate cancer screening programme.

Men with genes that increase the risk of prostate cancer should have annual checks from the age of 40, research has shown.

A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph ...